Aug 6 |
ONVO Announces Earnings and Notes Potential for Acquisition
|
Jul 18 |
Top 3 Health Care Stocks Which Could Rescue Your Portfolio In July
|
Jul 16 |
Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
|
Jun 4 |
ONVO Increases Cash and Improves Prospects
|
May 21 |
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
|
May 14 |
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
|
May 9 |
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
|
May 1 |
ONVO Announces Very Positive Phase 2 Results
|
Apr 15 |
Why Organovo Stock Is Up Today
|
Apr 15 |
Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis
|